source
- EyePoint cuts half its staff and ends wet AMD trials after second Phase 3 failure, pivots to diabetic macular edemaEyePoint said it is launching a strategic review after its investigational drug duravyu failed another Phase 3 study in wet age‑related macular degeneration. The company reported that the top‑line…
- EyePoint's Phase 3 trial fails, prompting 53% staff cuts; Lilly signs China drug delivery partnershipEyePoint, a Watertown, Massachusetts biotech, reported that its experimental therapy did not meet primary endpoints in a Phase 3 study, marking a setback for the company. Following the trial failu…Endpoints · 14h agoNegative readoutNegative